Leerink Partners Downgrades Mirati Therapeutics (MRTX) to Market Perform
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Mirati Therapeutics Provides Progress Update On Current Clinical Trials
June 5, 2016 9:00 AM EDTSAN DIEGO, June 5, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today provided an update on three current ongoing clinical programs in patients with non-small cell lung cancer (NSCLC) and other solid tumors.
"We are making significant progress in the development of our pipeline as our ongoing clinical programs are showing meaningful results," said Charles M. Baum, M.D., Ph.D., president and CEO. "We have confirmed responses including sustained activity in our glesatinib program, and encouraging signs of early efficacy from sitravatinib. These data demonstrate our ability to advance our targeted oncology... More